Innate Pharma (IPHYF) Debt Ratio (2017 - 2025)

Innate Pharma's Debt Ratio history spans 9 years, with the latest figure at 0.36 for Q4 2025.

  • For Q4 2025, Debt Ratio rose 28.96% year-over-year to 0.36; the TTM value through Dec 2025 reached 0.05, up 11.01%, while the annual FY2025 figure was 0.36, 28.96% up from the prior year.
  • Debt Ratio reached 0.36 in Q4 2025 per IPHYF's latest filing, up from 0.28 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.36 in Q4 2025 to a low of 0.17 in Q4 2021.
  • Average Debt Ratio over 5 years is 0.25, with a median of 0.23 recorded in 2023.
  • Peak YoY movement for Debt Ratio: soared 166.44% in 2021, then increased 7.41% in 2023.
  • A 5-year view of Debt Ratio shows it stood at 0.17 in 2021, then increased by 28.15% to 0.21 in 2022, then increased by 7.41% to 0.23 in 2023, then increased by 22.56% to 0.28 in 2024, then grew by 28.96% to 0.36 in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Debt Ratio are 0.36 (Q4 2025), 0.28 (Q4 2024), and 0.23 (Q4 2023).